Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Related Articles
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 15, 2022
Cardiology’s AI Moment: Anumana’s Top Insights from ACC.25
#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…April 22, 2025
Anumana and AliveCor Collaborate to Advance ECG-AI Algorithms for Early Detection of Cardiac Diseases on Kardia Devices
Anumana announces collaboration with AliveCorJanuary 07, 2025
Mayo Clinic launches two new tech companies
JHC Online: Mayo Clinic has announced a new technology platform initiative to new clinical decision support tools, diagnostic insights, and care recommendations to help clinicians make faster and more accurate…November 09, 2021